Becton, Dickinson and Company $BDX Shares Purchased by Inlet Private Wealth LLC

Inlet Private Wealth LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1,515.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 22,620 shares of the medical instruments supplier’s stock after buying an additional 21,220 shares during the period. Inlet Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $4,390,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Focus Financial Network Inc. increased its stake in Becton, Dickinson and Company by 2.2% during the 3rd quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock valued at $504,000 after buying an additional 58 shares during the period. Phillips Wealth Planners LLC increased its stake in Becton, Dickinson and Company by 2.7% during the 3rd quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock valued at $430,000 after buying an additional 58 shares during the period. Union Bancaire Privee UBP SA boosted its position in shares of Becton, Dickinson and Company by 25.7% during the 4th quarter. Union Bancaire Privee UBP SA now owns 289 shares of the medical instruments supplier’s stock valued at $56,000 after purchasing an additional 59 shares in the last quarter. Legacy Solutions LLC boosted its position in shares of Becton, Dickinson and Company by 5.3% during the 4th quarter. Legacy Solutions LLC now owns 1,172 shares of the medical instruments supplier’s stock valued at $227,000 after purchasing an additional 59 shares in the last quarter. Finally, CX Institutional boosted its position in shares of Becton, Dickinson and Company by 3.6% during the 3rd quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock valued at $324,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the transaction, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 2,713 shares of company stock valued at $536,881. Corporate insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BDX. Argus reduced their price objective on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. Barclays began coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Bank of America raised their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Finally, Jefferies Financial Group reduced their price objective on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus target price of $191.62.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $155.13 on Tuesday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a 50-day moving average of $174.72 and a 200-day moving average of $186.24. The firm has a market cap of $44.17 billion, a price-to-earnings ratio of 25.31, a price-to-earnings-growth ratio of 11.20 and a beta of 0.29. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company had revenue of $4.49 billion during the quarter, compared to analysts’ expectations of $5.15 billion. During the same period last year, the company posted $3.43 earnings per share. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a stock repurchase program on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 68.52%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.